Explore
Validate
Learn
Western blot
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-24826 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MICALL2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 0.25 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells.
Min P, Zhang L, Wang Y, Qi C, Song Y, Bibi M, Zhang Y, Ma Y, Zhao X, Yu M, Du J
Frontiers in cell and developmental biology 2020;8:575903
Frontiers in cell and developmental biology 2020;8:575903
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HL-60 cells using a MILK2 polyclonal antibody (Product # PA5-24826) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Analysis of MICAL-L2 and c-Myc expression in lung adenocarcinoma (LUAD) tissues. (A) Immunohistochemical staining for MICAL-L2 in LUAD tissues. (B,C) Analysis of MICAL-L2 and c-Myc staining in LUAD tissues. (D) Analysis of The Cancer Genome Atlas (TCGA) database showed that MICAL-L2 is highly expressed in lung cancer tissues when compared with normal tissues. (E,F) MICAL-L2 protein expression in different non-small cell lung carcinoma (NSCLC) cell lines. * P < 0.05, ** P < 0.01, *** P < 0.001.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 The effects of MICAL-L2 knockdown on c-Myc expression in non-small cell lung carcinoma (NSCLC) cells. (A) Total protein extracts from A549 cells treated with small interfering RNAs targeting MICAL-L2 (siMICAL-L2) for 48 h were assessed for MICAL-L2 and c-Myc expression. *** P < 0.001 relative to cells expressing control siRNA. (B) Blots showing the protein expression of MICAL-L2 and c-Myc in lysates from H1299 cells transfected with siMICAL-L2. ** P < 0.01, *** P < 0.001 relative to cells expressing control siRNA. Data in (A) and (B) are presented as means +- SD of 3 determinations. (C) Representative immunofluorescence images of c-Myc staining in A549 cells transfected with siMICAL-L2. Scale bar, 5 mum.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 8 MICAL-L2 interacted with c-Myc. (A) Representative immunofluorescence images of MICAL-L2 (green), c-Myc (red), and nuclei (blue) staining in A549 and H1299 cells. (B) The binding of endogenous MICAL-L2 to c-Myc was detected in H1299 cells by co-immunoprecipitation assays. (C,D) Co-immunoprecipitation was performed with extracts from Cos-7 cells co-transfected with Flag-tagged c-Myc and HA-tagged MICAL-L2. (E) Schematic representation of the c-Myc domains (a). Cos-7 cells were co-transfected with HA-MICAL-L2 and a c-Myc mutant following which cell extracts were analyzed by Western blotting (b). Cos-7 cells were co-transfected with HA-MICAL-L2 and c-Myc mutant #2 following which cell extracts were analyzed using Immunofluorescence (c). (F) Schematic representation of the MICAL-L2 domains (a). Cos-7 cells were co-transfected with Flag-c-Myc and a MICAL-L2 mutant following which cell extracts were analyzed by Western blotting (b).
